Historically authorized alone for selected COVID-19 cases. FDA revoked this single-antibody authorization in April 2021 because resistant variants reduced its usefulness.
Profile scope: Bamlanivimab alone — revoked U.S. authorization. Confirm the exact product and route; formulations and combination products are not interchangeable.
Possible side effects
Older information describes loose stools and injection-site discomfort or bruising.
Serious risks and warning signs
Infusion reactions and severe allergy were concerns. New breathing problems, abnormal pulse, marked weakness, or confusion required urgent assessment. Revocation for variant resistance is not proof that a particular adverse reaction occurred.
A question for your healthcare team
Which details from a past infusion reaction should be included in my medical record?
What to do with this information
Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.
Sources
Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.